Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.19.1
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended 18 Months Ended 51 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2019
Mar. 31, 2019
Dec. 31, 2018
Disaggregation of Revenue [Line Items]            
Prior period performance obligation revenue recognized $ 8,400,000 $ 15,700,000        
Overpayments received period     10 years      
Overpayment reimbursement liability 35,600,000     $ 35,600,000 $ 35,600,000 $ 35,900,000
Revenue recognized       0    
Total revenues 222,451,000 254,914,000        
Contract liability 73,000,000.0     73,000,000.0 73,000,000.0 $ 91,100,000
Rayaldee            
Disaggregation of Revenue [Line Items]            
Revenue recognized 5,800,000 3,700,000        
Total revenues 12,734,000          
Transfer of intellectual property and other            
Disaggregation of Revenue [Line Items]            
Total revenues 18,259,000 15,748,000        
Pfizer | Collaborative Arrangement, Product            
Disaggregation of Revenue [Line Items]            
Revenue recognized         0  
Contract liability 65,700,000     $ 65,700,000 $ 65,700,000  
Pfizer | Collaborative Arrangement, Product | Transfer of intellectual property and other            
Disaggregation of Revenue [Line Items]            
Total revenues $ 17,400,000 $ 14,700,000